Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9924
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBellomo, Rinaldoen
dc.contributor.authorHonoré, P Men
dc.contributor.authorMatson, Jen
dc.contributor.authorRonco, Claudioen
dc.contributor.authorWinchester, Jen
dc.date.accessioned2015-05-15T23:12:40Z-
dc.date.available2015-05-15T23:12:40Z-
dc.date.issued2005-05-01en
dc.identifier.citationThe International Journal of Artificial Organs; 28(5): 450-8en
dc.identifier.govdoc15883959en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9924en
dc.description.abstractExtracorporeal blood purification treatment (EBT) methods have been used in the treatment of experimental and human SIRS/Sepsis in a variety of settings and with variable reports of efficacy and safety. Their role in the management of SIRS/Sepsis remains controversial.To develop consensus statements regarding important aspects of research, practice and technical management concerning EBT.Systematic review of published study. Evidence-based grading of information available. Consensus development regarding fundamental questions about EBT.Consensus was achieved on all questions posed during the conference. It was agreed that there is currently a clear biological rational for EBT in SIRS and Sepsis. It was agreed that conventional CVVH has sufficiently been shown not to be effective in SIRS/Sepsis in the absence of concomitant ARF and that other therapies such as plasmapheresis or high-volume hemofiltration or coupled plasma filtration adsorption appear more promising and should be tested in multicentre randomized controlled trials. Patients with ARF and SIRS/Sepsis should be treated differently from those with ARF alone even though current practice in this field is not well known. Patients with refractory septic shock should be considered for EBT. Appropriate end points for clinical trials can be defined and chosen according to the goals of the trial. Different technologies exist for EBT and better understanding of the merits and safety of each is needed as well as better standardization of methodology and dose.Broad consensus can be achieved on several aspects of EBT and can be used to inform clinical practice and to help guide the establishment of a future research agenda.en
dc.language.isoenen
dc.subject.otherAcute Kidney Injury.complications.therapyen
dc.subject.otherBiological Markersen
dc.subject.otherHemofiltration.methods.standardsen
dc.subject.otherHumansen
dc.subject.otherOutcome Assessment (Health Care).standardsen
dc.subject.otherSepsis.complications.therapyen
dc.titleExtracorporeal blood treatment (EBT) methods in SIRS/Sepsis.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternational Journal of Artificial Organsen
dc.identifier.affiliationDepartment of Intensive Care and Department of Medicine, Austin Hospital and Melbourne University, Melbourne - Australiaen
dc.description.pages450-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15883959en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 30, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.